Market Cap
$184.8B
GILD
GILEAD SCIENCES, INC.
$144.18 ▼ -2.25%
Prev close $147.50Market cap$184.8B
ConsensusStrong Buy
12-mo target$158.65 (+10.0%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)39 New Institutional Positions11 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on GILD right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$106.0B
Inst. Activity
39 buys / 11 sells
Insider Activity
$0.00 buy / $15.4M sell
Insider Net $
-$15.4M
SEC Reports
16
Congressional
4 trades
Price chart 30d -3.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Feb 2, 2027 fda_pdufa
PDUFA: GILD — Yeztugo in HIV pre-exposure prophylaxis — 2027-02-02
FDA target action date 2027-02-02 for GILD (GILEAD SCIENCES, INC.). Drug: Yeztugo. Indication: HIV p
Sep 22, 2026 Insider
Burkhart Erin surrendered for taxes 768 shares
SVP, Controllership @ $152.67 ($117.3K)
Sep 22, 2026 Insider
Burkhart Erin acquired via exercise 2,223 shares
SVP, Controllership
Sep 15, 2026 Insider
Dickinson Andrew D sold 3,000 shares
Chief Financial Officer @ $145.29 ($435.9K)
Aug 27, 2026 Event
Market Event
Original Approval — Type 4 - New Combination
Aug 18, 2026 Event
Gilead Sciences, Inc. v. Meritain Health, Inc.
Court ruling (ca4) — Docket: 25-01828
Aug 10, 2026 Congress
Jul 21, 2026 SEC Ro Khanna sell
$1,001 - $15,000 — House
Leerink Partners downgrades GILD to Market Perform — PT $127 (-4.7%)
ANALYST-DOWNGRADE — Impact 4/10
Analyst ratings buy % +3.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 37 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Aug 5, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Aug 5, 2026 | Needham | REITERATE | Buy | 50% |
| Jul 29, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| Jul 27, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jul 21, 2026 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Jul 8, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jul 7, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Jul 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 21 | 7 | 0 | 0 | 81% | |
| Aug 1, 2026 | 9 | 21 | 7 | 0 | 0 | 81% | |
| Jul 1, 2026 | 10 | 20 | 7 | 0 | 0 | 81% | |
| Jun 1, 2026 | 11 | 21 | 7 | 0 | 0 | 82% | |
| May 1, 2026 | 11 | 20 | 8 | 0 | 0 | 79% | |
| Apr 1, 2026 | 11 | 20 | 8 | 0 | 0 | 79% | |
| Mar 1, 2026 | 10 | 20 | 8 | 0 | 0 | 79% | |
| Feb 1, 2026 | 10 | 20 | 7 | 0 | 0 | 81% |
Price targets
Where 26 covering analysts think GILD trades over the next 12 months.
$158.65 +10.0% upside Buy
Current$144.18 Low$123.00 Median$163.50 High$180.00 26 analysts
$123.00$180.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 4 bullish, 2 bearish, 0 mixed, 10 neutral · avg impact 3.4/10.
BULLISHANALYST-UPGRADE2/10
Maxim Group upgrades GILD to Buy — PT $165 (+26.4%)
May 20, 2026
BEARISHANALYST-DOWNGRADE4/10
Leerink Partners downgrades GILD to Market Perform — PT $127 (-4.7%)
Jul 21, 2026
BULLISHANALYST-UPGRADE3/10
HSBC upgrades GILD to Buy — PT $155 (+18%)
Jul 6, 2026
NEUTRALCLUSTER2/10
GILD insiders, including Chairman & CEO Daniel O'Day and Director Anthony Welters, sold a total of ~
Sep 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Feb 2, 2027
fda_pdufa
PDUFA: GILD — Yeztugo in HIV pre-exposure prophylaxis — 2027-02-02
FDA target action date 2027-02-02 for GILD (GILEAD SCIENCES, INC.). Drug: Yeztugo. Indication: HIV pre-exposure prophylaxis. PDUFA target action date
Dec 23, 2026
fda_pdufa
PDUFA: GILD — anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (4L+) — 2026-12-23
FDA target action date 2026-12-23 for GILD (GILEAD SCIENCES, INC.). Drug: anitocabtagene autoleucel (anito-cel). Indication: relapsed or refractory mu
Sep 18, 2026
Clinical Trial
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
Phase Phase 2 — TERMINATED
Sep 18, 2026
Clinical Trial
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
Phase Phase 2 — COMPLETED
Sep 18, 2026
Clinical Trial
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.15 | $1.90–$2.68 | -13.1% | -0.2% | 6↑ 14↓ | $7.8B | 22 |
| Next Q | $2.19 | $1.92–$3.13 | 17.7% | -0.2% | 3↑ 16↓ | $8.1B | 20 |
| Current FY | $-0.43 | $-0.62–$-0.02 | -105.2% | -0.5% | 24↑ 2↓ | $30.7B | 27 |
| Next FY | $9.89 | $9.19–$11.10 | 2419.9% | -0.0% | 19↑ 6↓ | $32.7B | 26 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.148 | — |
| 7d ago | $2.148 | — |
| 30d ago | $2.152 | -0.004 |
| 60d ago | $2.202 | -0.054 |
| 90d ago | $2.076 | +0.072 |
Institutional ownership
Which big funds own GILD (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $106.0B total value (829,998,024 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, FMR. Net buying activity: 39 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 121,844,108 | $15.4B | 14.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 81,091,734 | $10.2B | 9.7% | — |
| FMR LLC | 66,870,816 | $8.4B | 8.0% | — |
| STATE STREET CORP | 61,216,552 | $7.7B | 7.3% | — |
| Capital World Investors | 40,988,975 | $5.2B | 4.9% | — |
| Invesco Ltd. | 39,819,151 | $5.0B | 4.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 35,316,168 | $4.5B | 4.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 30,065,642 | $3.8B | 3.6% | — |
| MORGAN STANLEY | 24,004,354 | $3.0B | 2.9% | — |
| DODGE & COX | 23,677,567 | $3.0B | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 21,965,555 | — | $2.8B |
| JPMORGAN CHASE & CO | TRIM | 33,992,410 | 20,820,621 | -38.7% | $2.6B |
| Capital Research Global Investors | TRIM | 27,127,533 | 19,393,296 | -28.5% | $2.5B |
| PeakShares LLC | NEW | — | 7,920 | — | $1.0B |
| Boston Partners | ADD | 4,255,122 | 6,017,958 | +41.4% | $761.6M |
| Qube Research & Technologies Ltd | DOUBLED | 121,052 | 3,086,166 | +2449.5% | $389.9M |
| CITIGROUP INC | ADD | 2,300,271 | 2,969,159 | +29.1% | $375.1M |
| ProShare Advisors LLC | ADD | 1,811,223 | 2,829,082 | +56.2% | $357.4M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 1,966,938 | 2,536,332 | +28.9% | $320.4M |
| D. E. Shaw & Co., Inc. | DOUBLED | 200,919 | 2,294,789 | +1042.1% | $289.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$15.4M — $0.00 bought, $15.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Burkhart Erin | SVP, Controllership | TAX W/H | 768 | $152.67 | $117.3K |
| Sep 22, 2026 | Burkhart Erin | SVP, Controllership | EXERCISE | 2,223 | — | — |
| Sep 15, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | 3,000 | $145.29 | $435.9K |
| Sep 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 600 | $145.29 | $87.2K |
| Sep 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 800 | $144.46 | $115.6K |
| Sep 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 1,600 | $143.69 | $229.9K |
| Sep 10, 2026 | Dickinson Andrew D | Chief Financial Officer | TAX W/H | 1,347 | $144.81 | $195.1K |
| Sep 10, 2026 | Dickinson Andrew D | Chief Financial Officer | EXERCISE | 2,797 | — | — |
| Sep 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | EXERCISE | 8,780 | — | — |
| Sep 10, 2026 | Berger Dietmar | Chief Medical Officer | TAX W/H | 263 | $144.81 | $38.1K |
Congressional trades
GILD trades disclosed by members of Congress, with disclosure delay.
3 members · 3 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Ro Khanna | D | HOUSE | SELL | $1,001 - $15,000 | Gilead Sciences Inc | Sep 7, 2026(29d) |
| May 6, 2026 | Jared Moskowitz | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Jun 22, 2026(48d) |
| May 6, 2026 | Jared Moskowitz | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Jun 22, 2026(48d) |
| Jan 27, 2026 | Joshua Gottheimer | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Feb 27, 2026(32d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GILD.
Shares short
18,304,875
Settlement Sep 15, 2026
Change vs prior
-20.4%
Semi-monthly cycle
Days to cover
3.6
At avg daily volume
Of shares outstanding
≈1.5%
Estimate — not % of float
All GILD filing & press-release reports (16)
- Maxim Group upgrades GILD to Buy — PT $165 (+26.4%)May 20, 2026
- Leerink Partners downgrades GILD to Market Perform — PT $127 (-4.7%)Jul 21, 2026
- HSBC upgrades GILD to Buy — PT $155 (+18%)Jul 6, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 21, 2026
- COURT-RULING reportAug 19, 2026
- CLUSTER reportAug 18, 2026
- COURT-RULING reportAug 14, 2026
- S-3ASR reportAug 6, 2026
- CLUSTER reportJul 16, 2026
- CLUSTER reportJun 16, 2026
- 424B5 reportMay 18, 2026
- 424B5 reportMay 14, 2026
- CLUSTER reportApr 16, 2026
- DEFA14A reportMar 20, 2026